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ABSTRACT Epsilon toxin (ETX), a pore-forming toxin produced by type B and D strains of Clostridium perfringens, mediates se-
vere enterotoxemia in livestock and possibly plays a role in human disease. During enterotoxemia, the nearly inactive ETX pro-
totoxin is produced in the intestines but thenmust be activated by proteolytic processing. The current study sought to examine
ETX prototoxin processing and activation ex vivo using the intestinal contents of a goat, a natural host species for ETX-mediated
disease. First, this study showed that the prototoxin has a KEIS N-terminal sequence with a molecular mass of 33,054 Da.When
the activation of ETX prototoxin ex vivo by goat small intestinal contents was assessed by SDS-PAGE, the prototoxin was pro-
cessed in a stepwise fashion into an ~27-kDa band or higher-molecular-mass material that could be toxin oligomers. Purified
ETX corresponding to the ~27-kDa band was cytotoxic. When it was biochemically characterized by mass spectrometry, the co-
presence of three ETX species, each with different C-terminal residues, was identified in the purified ~27-kDa ETX preparation.
Cytotoxicity of each of the three ETX species was then demonstrated using recombinant DNA approaches. Serine protease inhib-
itors blocked the initial proteotoxin processing, while carboxypeptidase inhibitors blocked further processing events. Taken
together, this study provides important new insights indicating that, in the intestinal lumen, serine protease (including trypsin
and possibly chymotrypsin) initiates the processing of the prototoxin but other proteases, including carboxypeptidases, then
process the prototoxin into multiple active and stable species.
IMPORTANCE Processing and activation by intestinal proteases is a prerequisite for ETX-induced toxicity. Previous studies had
characterized the activation of ETX using only arbitrarily chosen amounts of purified trypsin and/or chymotrypsin. Therefore,
the current study examined ETX activation ex vivo by natural host intestinal contents. These analyses demonstrated that (i) ETX
processing in host intestinal contents occurs in an ordered, stepwise fashion, (ii) processing of prototoxin by host intestinal con-
tents results in higher-molecular-mass material and 3 distinct ~27-kDa ETX species, and (iii) serine proteases, such as trypsin,
chymotrypsin, and other proteases, including carboxypeptidases, play a role in the activation of ETX by intestinal contents.
These studies provide new insights into the activation and processing of ETX and demonstrate that this process is more compli-
cated than previously appreciated.
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The Gram-positive, sporulating, anaerobic bacterium Clostrid-ium perfringens causes many important and diverse diseases in
humans and livestock (1). Epsilon toxin (ETX), a pore-forming,
single polypeptide, is only produced by toxinotypes B and D of
C. perfringens (2–4). Molecular Koch’s postulate analyses showed
that ETX production is essential when type D strains cause fatal
enterotoxemias in livestock (5). ETX is also a National Institute of
Allergy and Infectious Diseases category B priority toxin and a
former CDC select toxin because of its extreme potency (50%
lethal dose [LD50] of 70 ng/kg of body weight in mice) (4, 6),
which ranks ETX as the third most lethal clostridial toxin, behind
botulinum and tetanus neurotoxins (7). There were limited re-
ports of human disease involving ETX until a recent study sug-
gested that ETX may trigger multiple sclerosis (8–10).
Enterotoxemia begins when C. perfringens type B or D strains
secrete the ~33-kDa ETX prototoxin into the intestinal lumen (4,
11). To exert significant in vivo pathology or in vitro cytotoxic
activity, the secreted prototoxin must be proteolytically processed,
which increases its activity nearly 1,000-fold (12). Once activated,
ETX increases the intestinal mucosal permeability (13), which al-
lows the entry of ETX into the bloodstream, where it can then
travel to organs such as the brain and kidney to cause enterotox-
emia (14–16).
Purified trypsin or -chymotrypsin can activate ETX proto-
toxin in vitro (4, 12, 17). Edman degradation analyses by Minami
et al. and others demonstrated that treatment with an arbitrarily
chosen amount of purified trypsin removes the 13 N-terminal
amino acids from the prototoxin (4, 11). Matrix-assisted laser
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desorption ionization–time of flight mass spectrometry (MALDI-
TOF MS) analyses showed that this trypsin treatment of proto-
toxin removes the 23 C-terminal amino acids of ETX, while treat-
ment of prototoxin with -chymotrypsin in the presence of
trypsin cleaves away the 29 C-terminal ETX amino acids; this C
terminus removal is required for ETX activation (4, 18).
The effects of natural host small intestinal contents on the pro-
teolytic processing/activation of ETX prototoxin have not been
evaluated. This issue is important since (i) ETX is secreted by
C. perfringens types B and D into the jejunal and ileal lumen but
rarely into the colon of naturally infected hosts (mainly goats and
sheep) (15, 16, 19), (ii) ETX increases small intestinal permeability
in rodent models (13), and (iii) ETX causes intestinal damage in
naturally infected goats (15, 19). In addition to trypsin and chy-
motrypsin, intestinal fluid contains other proteases, including
elastase, enteropeptidase, and carboxypeptidases (20), so it is pos-
sible those proteases also play a role in ETX activation/proteolytic
processing in the intestine.
To address and characterize the proteolytic processing and ac-
tivation of ETX prototoxin by intestinal proteases at native con-
centrations, the current study examined the ex vivo effects of goat
small intestinal contents on native ETX prototoxin. By amino acid
sequencing and mass spectrometry, the processing of prototoxin
by goat intestinal contents was examined. In addition, inhibitor
studies examined steps in this ex vivoprototoxin processing. These
studies provide new insights into the activation of this powerful
toxin.
RESULTS
Prototoxin purification and analysis. ETX prototoxin was puri-
fied as previously described (21–23); the purity and identity of this
preparation were assessed by SDS-PAGE with Coomassie staining
and Western blotting (Fig. 1A and B). Since the precise identity of
prototoxin has been unclear, the purified prototoxin was sub-
jected to both Edman degradation amino acid sequencing and
liquid chromatography (LC)– electrospray ionization (ESI)-TOF
MS for mass determination. Edman sequencing showed that the N
terminus of the prototoxin begins with the sequence KEIS
(Fig. 1C). LC–ESI-TOF MS of the purified prototoxin detected a
protein of 33,054.0 Da, which is within 2 Da of the predicted
molecular mass for the ETX prototoxin fromC. perfringens type D
strain NCTC8346 (GenBank accession number AAA23236.1)
(Fig. 1D and E).
Activationof the ETXprototoxin by goat intestinal contents.
The total trypsinlike protease activity in the intestinal contents
was calculated using the Pierce colorimetric protease assay kit,
which identified ~1 g/l of this activity in intestinal contents.
Using this value as a crude benchmark of proteolytic activity, 5g
of ETX prototoxin was treated for 60 min at 37°C with 10 g of
purified trypsin, 10g of purified chymotrypsin, a mixture of 5g
each of purified trypsin and chymotrypsin, or 10 l of goat intes-
tinal contents. Following the addition of a broad-range protease
inhibitor, each mixture was diluted in Dulbecco’s phosphate-
buffered saline (dPBS) and added to a confluent monolayer of
MDCK-II cells (60 min at 37°C). Cytotoxicity was measured by
lactose dehydrogenase (LDH) release and found to be equivalent
among the 4 proteolysis conditions tested, with a value of ~60%
cell death (Fig. 2). ETX prototoxin was inactive without protease
treatment.
Time course of ex vivo proteolytic processing and activation
of ETX prototoxin by goat intestinal contents. Earlier studies of
ETX prototoxin processing/activation used arbitrarily chosen
amounts of purified trypsin, with or without chymotrypsin, and a
single digestion time that ranged from 30 to 120 min (4). To char-
acterize the ex vivo proteolytic processing/activation of ETX pro-
totoxin in physiologically relevant goat intestinal contents, those
processes were observed over 90 min using SDS-PAGE with Coo-
massie staining, Western blotting, and an MDCK cell cytotoxicity
assay (Fig. 3A to C). During the treatment with intestinal contents,
proteolysis of prototoxin began within 1 min, while the activation
of ETX-induced MDCK cell cytotoxicity began within 5 min.
With longer treatment, a ladder-like pattern of ETX cleavage was
observed by SDS-PAGE and Western blotting, with approxi-
mately 3 intermediate ETX bands eventually observed. The cyto-
FIG 1 Purification and characterization of ETX prototoxin. (A and B) The
purity and identity of ETX prototoxin were assessed by SDS-PAGE, followed
by Coomassie staining (A) or Western blotting (B). (C) Schematics of the N
terminus of full-length toxin encoded by the etx open reading frame (ORF),
the predicted N-terminal start site of the ETX prototoxin, and the N-terminal
start site of the ETX prototoxin as determined by Edman degradation. The
N-terminal sequence of the purified prototoxin is shown by boldface and
underlining. (D and E) The ETX prototoxin was subjected to LC–ESI-TOF MS
to determine its intact molecular weight (M.W.) (D), and the molecular weight
from this result is compared against the predicted prototoxin molecular
weight to deduce the C terminus (E).
Freedman et al.
2 ® mbio.asm.org September/October 2014 Volume 5 Issue 5 e01994-14
toxic properties of ETX in goat intestinal contents then remained
relatively constant until ~30 min of treatment, when there was an
~25% increase in cytotoxic activity. This increase in cytotoxicity
correlated with the appearance of a major ETX band of ~27 kDa
(Fig. 3A); that band remained present in the goat intestinal con-
tents with incubation up to 120 min, as visualized by SDS-PAGE
(data not shown).
For comparison, the prototoxin was digested with the same
nonphysiological, large amount of trypsin (1:25,g ETX/g tryp-
sin) used by Minami et al. (4). Within 30 min of digestion, ETX
was undetectable by Coomassie staining and only weakly detect-
able by Western blotting. However, ETX remained strongly de-
tectable by Coomassie staining or Western blotting after a 90-min
treatment with purified trypsin used at an activity equivalent to
that measured in goat intestinal content (Fig. 3D).
During this kinetics experiment, we noted that the 90-min
sample retained the same cytotoxicity as prototoxin samples di-
gested for 30 min, even though there was apparently much more
ETX-related protein in the 30-min sample. However, more high-
molecular-weight proteinaceous material was noted in the 90-min
versus the 30-min treatment sample (Fig. 3A). To evaluate
whether this material might include an ETX species that was not
FIG 2 Goat intestinal contents activate ETX. Purified ETX prototoxin was
incubated for 60 min with 10g of the indicated proteases (total or combined)
or with goat intestinal contents as indicated on the x axis. Following incuba-
tion, protease inhibitor was added and each mixture was then applied to
MDCK-II cells for 60 min. The percent cytotoxicity (y axis) was measured by
LDH release. As was expected, cytotoxicity was not observed when MDCK cells
were treated with prototoxin alone. Goat intestinal contents or purified pro-
teases alone did not cause MDCK cytotoxicity (not shown). The data represent
three independent experiments, and error bars represent the standard errors.
FIG 3 Goat intestinal contents activate ETX prototoxin in a precise, stepwise pattern. (A and B) ETX prototoxin was incubated with goat intestinal contents
(i.c.) for the indicated times, and the resulting processed forms of ETX were visualized using SDS-PAGE and Coomassie blue staining (A) or Western blotting (B),
demonstrating a stepwise pattern of processing and activation. Aliquots of the same digestion products (containing 5g of toxin) were used to treat MDCK cells,
and cytotoxicity was measured using an LDH release assay. This analysis showed that the appearance of an ETX species at 30 min, which then remains stable for
a significant period of time, correlates with an ~30% increase in ETX-induced cytotoxicity. (C) Goat intestinal contents or purified proteases alone did not cause
MDCK cytotoxicity (not shown). Three experiments were performed independently, and error bars represent the standard errors. (D) Using goat intestinal
contents (90 min), physiologic levels of trypsin (90 min), or the amount of trypsin used by Minami et al. (30 min), the stability of ETX was assessed by SDS-PAGE
and Coomassie blue staining (left) or Western blotting (right). (E) Alexa Fluor 488-labeled prototoxin was treated with intestinal contents for 90 min at 37°C and
subjected to SDS-PAGE and fluorescent imaging.
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reactive with the ETX polyclonal antibody in Western blot assays,
Alexa Fluor 488-labeled ETX was incubated for 90 min with goat
intestinal contents. The results of this study showed small
amounts of a fluorescent 27-kDa protein, along with fluorescent
high-molecular-mass material (Fig. 3E).
The effects of class-specific protease inhibitors on ETX pro-
cessing and activation. To better understand the results shown in
Fig. 3, we examined which protease classes were important for the
activation of the ETX prototoxin by caprine intestinal contents.
For this purpose, caprine intestinal contents were incubated with
class-specific protease inhibitors for 30 min at room temperature
before being mixed with ETX prototoxin for 90 min at 37°C. Only
the Bowman-Birk inhibitor, which targets serine proteases (e.g.,
trypsin and chymotrypsin), blocked MDCK cytotoxicity (Fig. 4A)
and prevented most but not all of the initial proteolytic processing
of prototoxin by the intestinal contents (Fig. 4B). Pretreatment of
the intestinal contents with carboxypeptidase inhibitor prevented
the extensive processing of ETX, with no ~27-kDa species detect-
able (Fig. 4B). Similarly, treatment of the prototoxin with purified
trypsin and chymotrypsin resulted in an ETX band of the same
size as observed in the presence of intestinal contents and carboxy-
peptidase inhibitors (Fig. 4C).
Purification and characterization of the ~27-kDa ETX spe-
cies produced during the activation of prototoxin by intestinal
contents. Given the presence of the ~27-kDa ETX band after pro-
longed treatment with goat intestinal contents, this ETX species
was analyzed further. The ~27-kDa ETX species was purified, the
purity was then demonstrated by SDS-PAGE with Coomassie
staining, and the identity of ETX in the preparation was confirmed
by Western blotting (Fig. 5A and B). This purified ~27-kDa ETX
preparation (5 g/ml) was biologically active, as tested by cyto-
toxicity on MDCK-II cells (Fig. 5C). Edman degradation analysis
revealed the first 6 amino acids of the ~27-kDa ETX species to be
KASYDN, indicating trypsin cleavage of the first 13 N-terminal
amino acids from the prototoxin (Fig. 6A).
Interestingly, LC–ESI-TOF MS for intact-mass analysis of the
purified ~27-kDa ETX species produced after a 90-min treatment
with intestinal contents revealed the presence of three distinct
ETX species with demonstrated molecular masses of 27,688.0,
27,801.4, and 27,900 Da (Fig. 6B). Molecular mass prediction
based on the epsilon toxin sequence revealed that proteins span-
ning from K14 to N262, N263, or V264 would have molecular
masses of 27687.84, 27801.94, or 27901.08 Da, respectively
(Fig. 6C).
Evaluation of the cytotoxic activity of the~27-kDaETX frag-
ments using recombinant proteins.The cytotoxic activity of each
of the three identified ETX species produced after proteolytic pro-
cessing by goat intestinal contents was evaluated using a recombi-
nant protein approach. For this purpose, each of the three ETX
fragments, along with ETX fragments corresponding to those pro-
duced by treatment of native prototoxin with purified trypsin or a
combination of purified trypsin and-chymotrypsin (based upon
previous results [4]), was expressed in Escherichia coli as maltose-
binding protein (MBP) fusion proteins (Fig. 7A). Following ex-
pression and purification of the MBP-rETX (recombinant ETX)
fragments, the fragments were liberated from the MBP solubility
tag and used to test MDCK cell cytotoxicity (Fig. 7B and C).
By measuring MDCK cell cytotoxicity by the LDH release as-
say, it was determined that the rETX fragments comprising amino
acids 14 to 262, 14 to 263, and 14 to 264 (rETX14 –262, rETX14 –263,
FIG 4 Characterization of the effects of protease inhibitors on ETX processing and activation in goat intestinal contents. Goat intestinal contents (i.c.) were
pretreated with the indicated protease inhibitors for 30 min at room temperature, and ETX was then added for 90 min at 37°C. (A and B) MDCK cell cytotoxicity
was measured (n 3) (A), and the processing was analyzed by SDS-PAGE and Coomassie staining (left) and Western blotting (right) (B). (C) ETX activated in
the presence of carboxypeptidase inhibitors was compared to ETX activated by trypsin and chymotrypsin using SDS-PAGE and Coomassie staining (left) and
Western blotting (right). SPI, serine protease inhibitor; CPI, carboxypeptidase inhibitor; E64, E-64 cysteine protease inhibitor.
Freedman et al.
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and rETX14 –264 fragments) each represent cytotoxic forms of
ETX. For comparison, the rETX14 –267 and rETX14 –273 fragments
(corresponding to trypsin–-chymotrypsin- and trypsin-
activated forms, respectively) also possessed cytotoxic activity (4).
Furthermore, the cytotoxic properties of the rETX14 –267 and
rETX14 –273 fragments were similar to those of the rETX14 –262,
rETX14 –263, and rETX14 –264 fragments. The negative controls, i.e.,
full-length rETX prototoxin or MBP alone, were inactive, con-
firming that the observed cytotoxicity was specifically due to the
activity of those rETX fragments rather than activity from con-
taminating E. coli proteins (Fig. 7D).
DISCUSSION
This study reports several important results with substantial im-
port for our understanding of ETX processing and activation.
First, it resolves the precise biochemical identity of the secreted
ETX prototoxin, which had remained unclear in the literature.
Hunter et al. determined by SDS-PAGE that the prototoxin has an
approximate molecular mass of ~33 kDa, with a predicted
N-terminal sequence of KEISNTVSNEM based upon in silico
analysis of the deduced etx open reading frame sequence (11).
However, the N-terminal sequence and the precise mass of the
prototoxin were not experimentally determined in their study.
The prediction of Hunter et al. (11) for the prototoxin N-terminal
sequence was in general agreement with earlier amino acid-
sequencing results reported by Bhown and Habeeb in 1977, who
determined the N-terminal sequence of the ETX prototoxin to be
KEICB(N or R)PVSYEM (11, 17). More different were the results
reported by Minami et al., where the ETX prototoxin was found to
have a molecular mass of 32,307 Da and an N-terminal sequence
of VSNEM (4). The results from the current study match exactly
the bioinformatic predictions of Hunter et al. regarding the iden-
tity of ETX prototoxin (11), i.e., Edman degradation determined
that the ETX prototoxin has an N-terminal sequence of KEIS,
while LC–ESI-TOF MS detected a molecular mass of 33,054 Da
(Fig. 1C to E). These results match the predicted molecular mass
of 33,055.99 Da for a protein encoded by the etx open reading
frame of type D strain NCTC8346 that has a KEIS N-terminal
sequence (GenBank accession number AAA23236.1). It is not
clear whether the prototoxin characterization differences between
Minami et al. and the other studies are attributable to strain-
dependent differences in prototoxin processing during secretion
or have another explanation. Any observed differences in the pro-
totoxin characterization results are not due to strain-dependent
sequence variation, since the N-terminal amino acid sequence of
ETX is identical for all strains examined to date (GenBank acces-
sion numbers Q02307, AEH25946, ADF42572, AFQ89891,
1UYJ_A, AFP43229, AFN42326, WP_00345888, and
ADU04573).
Previous studies of the proteolytic processing and activation of
ETX prototoxin provided considerable insights into the biology of
this potent pore-forming toxin (3, 4, 12, 18, 24, 25). For example,
earlier studies revealed that the ETX prototoxin is ~1,000 times
less active than proteolytically activated ETX (12). However, the
nature of prototoxin proteolytic processing and activation during
disease has not been clear. Purified-protease ofC. perfringens can
process and activate the ETX prototoxin (4), but the physiologic
importance of this effect is under question since many ETX-
producing type B and D strains, including strain NCTC8346 used
for purifying prototoxin in this study, do not carry the gene en-
coding -protease (26). Furthermore, even those type B and D
strains encoding -protease typically cannot self-process or acti-
vate their prototoxin (26). A single -protease-negative type D
strain was identified that produces a partially processed ETX using
an intracellular protease, but this effect is not shared by other type
B and D strains surveyed and only produces a weakly activated
ETX (26).
Those findings made it apparent that intestinal proteases play a
major role in the processing and activation of prototoxin after its
secretion by C. perfringens into the intestinal lumen during type B
or D disease. Consistent with this view, several previous studies of
FIG 5 Purification and cytotoxicity of the stable ~27-kDa ETX produced by
treatment with goat intestinal contents. (A and B) The stable ~27-kDa ETX
identified in the experiments whose results are shown in Fig. 3 was purified by
ion-exchange chromatography, and its purity was assessed by SDS-PAGE fol-
lowed by Coomassie blue staining (A) and its identity confirmed by Western
blotting (B). (C) The resulting ETX preparation was used to treat MDCK cells
for 1 h, and cytotoxicity was again measured by LDH release, demonstrating
that the purified ~27-kDa ETX material is biologically active. Goat intestinal
contents or purified proteases alone did not cause MDCK cytotoxicity (not
shown). Error bars represent standard errors (n 3).
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ETX prototoxin activation used purified or crude trypsin and
-chymotrypsin preparations to study prototoxin processing and
activation (4, 11). While informative, that approach has at least
two major limitations. First, those previous experiments used
trypsin and -chymotrypsin, alone or in combination, at appar-
ently arbitrarily chosen concentrations (4). Second, a number of
proteases other than trypsin and chymotrypsin are present in the
mammalian intestinal lumen and those enzymes may also con-
tribute to ETX prototoxin processing and activation (20). Because
of those concerns, we hypothesized that prototoxin processing in
the intestinal contents of a host animal may differ from the pro-
totoxin processing reported using the purified intestinal proteases
trypsin and chymotrypsin, either alone or in combination.
To address this proposition, the small intestinal contents from
a healthy adult goat were used to treat purified prototoxin ex vivo.
This experiment revealed that prototoxin incubated with natural
small intestinal contents from a healthy adult of a natural host
species for the disease causes the characteristic LDH release, nu-
clear shrinkage, and cellular swelling in MDCK cells, as previously
described for active ETX (23, 27). This result demonstrated clearly
for the first time that natural intestinal contents can activate the
ETX prototoxin (Fig. 2).
FIG 6 Characterization of purified ~27-kDa ETX activated by goat intestinal contents (A). The purified ~27-kDa ETX preparation was subjected to Edman
sequencing, and the resulting N-terminal sequence was compared to the sequence of the prototoxin N terminus. The N-terminal sequences identified are
indicated by boldface and underlining. (B) The purified and processed ~27-kDa ETX preparation was subjected to LC–ESI-TOF MS, which demonstrated the
presence of three protein species of 27,688.0, 27901.4, and 27,900.0 Da. (C) Based upon the molecular masses, the predicted molecular weights were used to map
the C termini of these species. The identified C termini of the ETX species are shown with the C termini of prototoxin and ETX treated with trypsin or with trypsin
and chymotrypsin for reference.
Freedman et al.
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Previous studies using purified trypsin and -chymotrypsin
only tested ETX activity after 60 min of prototoxin incubation
with those proteases (4), i.e., no time course study was performed
to examine the kinetics of ETX processing and activation at vari-
ous protease treatment times. Therefore, another contribution of
the current study involves characterizing prototoxin activation
over time. The results of this analysis revealed that, after even very
brief (1-min) contact with host intestinal contents, prototoxin
cleavage was detectable. However, when the prototoxin was tested
for activity using the MDCK cytotoxicity model, measurable cy-
totoxicity developed after a 5-min incubation with goat intestinal
contents (Fig. 3). This result demonstrates for the first time that
natural intestinal contents are extremely efficient at activating the
prototoxin. Coupling these activation kinetics with the size of the
initially observed ETX species produced upon treatment with in-
testinal fluid suggests a scenario for initial prototoxin processing,
i.e., the first step of ETX prototoxin activation likely involves re-
moval of the N terminus by trypsin, since this effect does not
directly trigger cytotoxicity (18). If so, this effect is then rapidly
followed by the removal of C-terminal residues, as required for the
development of cytotoxicity (4, 18).
Another contribution of this time course study is the first evi-
dence that natural ETX processing and activation follow a step-
wise pattern. After a 5-min treatment with intestinal contents, the
intact prototoxin was no longer detectable by SDS-PAGE and cy-
totoxicity had developed. This development of cytotoxic activity
was accompanied by the appearance of an ~30-kDa processed
ETX species that was smaller than the first ETX species processed.
After a 20-min treatment with intestinal contents, an even smaller
ETX species of ~27 kDa became detectable by SDS-PAGE. By
30 min of treatment, this ETX species had accumulated signifi-
cantly, along with a further ~25% increase in MDCK cell cytotox-
icity (Fig. 3). The ~27-kDa band persisted in the intestinal con-
tents for up to 120 min (data not shown). It is notable that the
stability of this ETX species would not have been appreciated by
SDS-PAGE with Coomassie staining if the same high concentra-
tions of purified trypsin or trypsin and chymotrypsin employed in
previous studies had been used (4, 18); however, a stable ETX
band slightly larger than 27 kDa was also observed by using phys-
iologic concentrations of purified trypsin in this study.
Despite its persistence, the ~27-kDa ETX band diminished by
90 to 120 min of treatment with goat intestinal contents compared
to its levels at earlier treatment time points, even though cytotox-
icity remained high. This inconsistency was addressed using Alexa
Fluor 488-labeled ETX prototoxin, which showed the presence of
multiple fluorescently labeled ETX species at molecular masses of
between ~150 and250 kDa (Fig. 3E) after 90 min of incubation
with goat intestinal fluid. This shift of some ETX to higher-
molecular-mass forms explains the high MDCK cell cytotoxicity
at 90 min despite the presence of small amounts of ETX detectable
by Western blotting using an anti-ETX polyclonal antibody. The
failure of Western blot assays to detect the high-Mr ETX forms
after extended treatment with intestinal contents could be due to
the epitopes recognized by this antibody being inaccessible in the
high-Mr ETX forms. These high-Mr ETX species could represent
either spontaneous oligomer formation involving processed ETX
or interactions between processed ETX and proteins in the intes-
tinal contents.
Because of its stability in the intestinal contents, the ~27-kDa
ETX species was purified to 95% homogeneity as detected by
SDS-PAGE, followed by Coomassie staining or Western blotting
(Fig. 5A and B). The purified ~27-kDa ETX preparation was active
on MDCK cells (Fig. 4C). When Edman sequencing was per-
formed on this species, it identified a single N-terminal sequence,
KASYDN, (Fig. 6A), which is consistent with trypsin cleavage be-
tween residues 13 and 14 of the prototoxin, as noted previously by
Minami et al. and Hunter et al. when prototoxin was treated with
purified trypsin in combination with purified chymotrypsin (4,
11).
Removing the C-terminal amino acids from the prototoxin is
required for the activation of ETX cytotoxic activity (18), so the C
terminus of the ~27-kDa ETX species was deduced by LC–ESI-
TOF MS analyses. Those analyses did not detect ETX species with
molecular masses of 28,973.3 Da or 28,321.5 Da, as would be
expected if the current model (4) were correct that activated ETX
FIG 7 Recombinant ETX species corresponding to those produced by treat-
ment of prototoxin with goat intestinal contents are cytotoxic in vitro. (A) To
confirm whether any of the 3 ~27-kDa ETX species identified following treat-
ment with goat intestinal contents are active, the resulting ETX fragments were
cloned, expressed as MBP fusion proteins, and purified from E. coli. (B and C)
Following liberation of the ETX species from the MBP tag, the presence of
appropriately sized bands was visualized by SDS-PAGE followed by Western
blotting (B) or Coomassie blue staining (C). (D) The percent cytotoxicity of
MDCK cells treated with the rETX fragments was measured using LDH re-
lease. rETX14 –295 and MBP alone were used as negative controls to ensure that
cytotoxicity was from the resultant rETX fragments and not from contaminat-
ing protein. Error bars represent standard errors (n 3).
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species are only produced from cleavage by trypsin or trypsin–-
chymotrypsin, respectively. Instead, three ETX species with mo-
lecular masses of 27,688.0, 27,801.4, and 27,900 Da were detected.
Those masses correspond precisely to ETX molecules cleaved by
trypsin at the N terminus and processed at the C terminus to
amino acids N262, N263, and V264 (Fig. 6B and C). This result
provided the first evidence that proteases other than trypsin,
-chymotrypsin, or perhaps, occasionally, C. perfringens pro-
teases play a role in ETX activation in the host small intestine.
We hypothesized that, following the initial cleavage of the C
terminus by the endopeptidases trypsin and/or -chymotrypsin
(or perhaps another serine endoprotease in the intestinal con-
tents), further C-terminal processing is initiated by intestinal car-
boxypeptidases. In support of this hypothesis, the results of using
protease inhibitors indicated that serine proteases (which include
trypsin and chymotrypsin) in goat intestinal contents are the ma-
jor initial processors and activators of the ETX prototoxin (Fig. 4A
and B). However, partial inhibition of late-stage ETX processing
was also observed by using a carboxypeptidase inhibitor, produc-
ing an ETX band of a size similar to that produced by a 90-min
treatment with purified trypsin and chymotrypsin at physiological
amounts. These results strongly suggest the involvement of car-
boxypeptidases in late-stage intestinal content processing to cre-
ate the ~27-kDa ETX species (Fig. 4C).
Because of the presence of three ETX species in the purified
~27-kDa ETX preparation, it was important to assess which indi-
vidual ETX species possessed cytotoxic activity. For this purpose,
each ETX species was cloned, expressed recombinantly in E. coli,
purified, and tested on MDCK cells. The results from these assays
indicated that all three individual ETX species are cytotoxic
(Fig. 7), supporting a potential pathogenesis role for these ETX
fragments during C. perfringens type B and D infections.
In summary, the current studies for the first time investigated
the activation and processing of epsilon prototoxin using the in-
testinal contents of a natural host. Under these conditions, the
presence of multiple species of the activated toxin was detected.
Future studies should examine the ETX species present in the large
complexes identified in this study and whether variations in intes-
tinal contents from different species or animals of different ages
and physiologies affect the processing of ETX prototoxin and, in
turn, the activity of ETX during in vivo disease, potentially ex-
plaining why certain animals do not suffer from disease caused by
C. perfringens types B and D. However, the current findings sig-
nificantly affect the understanding of this important toxin, partic-
ularly by identifying a role for other proteases besides trypsin and
chymotrypsin in the processing and activation of ETX and by
demonstrating that the processing is more complex and heterog-
enous than previously appreciated.
MATERIALS AND METHODS
Prototoxin purification and labelingwith Alexa Fluor 488. Epsilon pro-
totoxin from C. perfringens type D strain NCTC8346 was purified to elec-
trophoretic homogeneity as previously described (21–23). The prototoxin
concentration was determined using a bicinchoninic assay (BCA) kit as
recommended by the manufacturer (Pierce). The prototoxin was labeled
with Alexa Fluor 488 as described previously (23).
ETX Western blotting. Samples containing ETX were subjected to
Western blotting using polyclonal rabbit anti-ETX antibody (BEI Re-
sources) as described previously (21, 26).
Cell culture. Madin-Darby canine kidney (MDCK-II) cells were cul-
tured and maintained in a 50/50 (vol/vol) mix of Dulbecco’s modified
Eagle’s medium (DMEM, Sigma) and Ham’s F12 nutrient mixture
(Sigma) containing 8% fetal bovine serum, 1% glutamine, 100 units/ml of
penicillin, and 100 mg/ml streptomycin. Cells were cultured in cell culture
flasks at 37°C in 5% atmospheric CO2.
Goat small intestinal contents. A healthy adult male Anglo Nubian
goat was euthanized by an overdose of sodium barbiturate (Beuthanasia;
Schering-Plough Animal Health, Kenilworth, NJ), and the contents were
harvested from the jejunum and stored at 80°C until use. This proce-
dure was approved by the University of California—Davis IACUC (per-
mit number 16383). The intestinal contents were thawed, and solid ma-
terial was removed by two rounds of centrifugation at 15,000  g. The
resulting intestinal contents were aliquoted and stored at 80°C until
needed. Total protease activity was estimated using a colorimetric pro-
tease assay kit (Pierce) and was found to be ~1 g/l.
Purification of ETX species after treatmentwith goat intestinal con-
tents.ETX prototoxin was treated at 37°C with goat intestinal contents for
90 min. Following this incubation, Complete protease inhibitor cocktail
(Roche) was added, the contents containing ETX were diluted in phos-
phate buffer, and the intestinal content-treated ETX species was purified
with an AKTAprime liquid chromatography system, using DEAE support
resin. Fractions containing the intestinal content-treated ETX product
were pooled and concentrated, and concentrations were determined us-
ing the BCA method as described above.
Edman degradation amino acid sequencing of ETX prototoxin and
the ~27-kDa ETX species after treatment with goat intestinal contents.
The N-terminal sequences of ETX prototoxin and the ~27-kDa ETX spe-
cies produced by extended treatment with goat intestinal contents were
determined using Edman degradation amino acid sequencing, performed
at the University of California—Davis Proteomics Core Facility. A mini-
mum of 4 cycles was used to determine the N-terminal sequence, as well as
to confirm the identity of the proteins.
Capillary LC–ESI-TOF MS analysis for molecular-weight determi-
nation. Protein samples were analyzed using capillary LC–ESI-TOF MS.
Samples were loaded onto a PRLP-S column (5-m particle size, 1,000-Å
pore size, 300-m inner diameter by 100 mm; Thermo Fisher) on the LC
system (Ultimate 3000; Dionex, Sunnyvale, CA). The LC system was di-
rectly coupled to an electrospray ionization time-of-flight mass spectrom-
eter (micrOTOF; BrukerDaltonics, Billerica, MA). Chromatographic sep-
aration was performed at a constant flow rate of 3.5l/min using a binary
solvent system (solvent A, 2.5% acetonitrile, 0.1% formic acid; solvent B,
80% acetonitrile, 0.1% formic acid) and a linear gradient program (0 to
5 min, 5% B; 5 to 10 min, 5 to 30% B; 10 to 30 min, 30 to 75% B; 30 to
35 min, 75 to 100% B; 35 to 45 min, 100 to 5% B; and 45 to 60 min, 5% B).
Mass spectra were acquired in positive ion mode over the mass range m/z
50 to 3,000. ESI spectra were deconvoluted to obtain molecular ion masses
with DataAnalysis 3.3 (Bruker Daltonics, Billerica, MA) with an accuracy
of 1 to 2 Da.
Recombinant ETXexpression constructs and recombinant ETXpu-
rification. rETX truncation fragments were constructed based upon the
mass spectrometry and Edman degradation results of the current study or
from previous results (4, 11) describing ETX processing. PCR was per-
formed using Taq polymerase (New England Biolabs) and the following
cycle conditions: 94°C for 5 min; 35 cycles of 94°C for 30 s, 50°C for 30 s,
and 68°C for 1 min; and 68°C for 5 min. All primers and constructs are
listed in Table 1. The forward primers contain a site for enterokinase
cleavage that was used following protein purification. The PCR products
and vector pMAL-c2x (New England Biolabs) were digested with EcoRI
and BamHI (New England Biolabs), the PCR products were ligated into
pMAL-c2x using Instant Sticky-end master mix (New England Biolabs),
and the plasmids were transformed into Escherichia coli chi1776 (ATCC)
in a manner that met E. coli 2 (EK2) plasmid system standards for biolog-
ical containment. The sequence of each construct was confirmed by DNA
sequencing at the University of Pittsburgh Genomics and Proteomics
Core Laboratories.
Transformants were grown in LB broth supplemented with 50 g/ml
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of ampicillin, 100 g/ml of DL-diaminopimelic acid, and 10 g/ml of
thymidine. For induction, E. coli chi1776 (ATCC) was grown to an optical
density at 600 nm (OD600) of 0.6 at 37°C before shifting the culture to
room temperature and inducing with 1 mM isopropyl--D-
thiogalactopyranoside (IPTG) for 2.5 h. Cells were harvested by centrifu-
gation and lysed by sonication, and MBP-rETX fusion proteins were pu-
rified over amylose resin according to the manufacturer’s instructions
(New England Biolabs). Purified MBP-rETX fusion proteins were then
cleaved with enterokinase before downstream assays.
Assays of ETX-inducedMDCK-II cytotoxicity. To measure cytotox-
icity, 10g of ETX prototoxin was treated for 1 h at 37°C with 10l of goat
intestinal contents, 10 g of pure trypsin (Sigma), 10 g of pure chymo-
trypsin (Sigma), or a mixture containing 5g each of trypsin and chymo-
trypsin. Trypsin-chymotrypsin inhibitor from Glycine max (Sigma) was
added to the treated samples, and 5 g of ETX in dPBS with Ca2 and
Mg2 (cellgro; Corning) was added to washed MDCK cells. The cells were
incubated with ETX at 37°C for 1 h. ETX prototoxin alone (no protease)
or (in the absence of prototoxin) goat intestinal contents, purified trypsin,
and purified chymotrypsin with protease inhibitors served as negative
controls for cytotoxicity. rETX fragments were used at a concentration of
5 g/ml. For these assays, buffer was used as the negative control. A time
course cytotoxicity study was performed using the same ratio of intestinal
contents to ETX as described above. Aliquots were removed at the time
points indicated in Fig. 2, 3, 4, and 5, and Complete protease inhibitor
cocktail (Roche) was added. In all iterations, cytotoxicity was measured
using a cytotoxicity detection kit (Roche) that measures lactose dehydro-
genase (LDH) release, and the results are expressed as the percentage of
total nonviable cells. Experiments were performed 3 times in duplicate;
mean values are shown and the standard errors were determined. When
broad-range protease inhibitors were utilized, each inhibitor was prein-
cubated with intestinal contents for 30 min at room temperature before
the addition of ETX and incubation at 37°C for 90 min. Inhibitors were
purchased from Sigma-Aldrich and used at final concentrations as fol-
lows: 10 M pepstatin A (aspartyl protease inhibitor), 10 M E-64 (cys-
teine protease inhibitor), 2g/l Bowman-Birk inhibitor (serine protease
inhibitor), and 0.3 g/l carboxypeptidase inhibitor (mammalian car-
boxypeptidase inhibitor).
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